FRIDAY, MAY 15, 2009 |
Registration opens at 10:00 am. Lunch buffet available from 12:00 |
13.00 – 13.05 |
Welcome & Opening words
J. San Miguel, J.L. Harousseau, M. Aapro |
13.05 – 13.30 |
Keynote lecture
R. Kyle |
|
|
SESSION I: Biology and prognostic Indicators
Chair: M. Aapro |
Each 12 minute presentation is preceded and followed by one interactive question using a keypad followed by 8 minutes discussion |
13.30 – 13.50 |
Phenotype of the myeloma cell. Clinical implications.
J. San Miguel |
13.50 – 14.10 |
Signal transduction and apoptosis.
C. Pellat
|
14.10 – 14.30 |
The use of cytogenetics for defining prognosis and tailoring treatment
J. Drach |
| |
SESSION II: The role of novel agents in front-line therapy in elderly patients
Chair: J. San Miguel |
Each 12 minute presentation is preceded and followed by one interactive question using a keypad followed by 8 minutes discussion |
14.30 – 14.50 |
Thalidomide
C. Hulin |
14.50 – 15.10 |
Bortezomib
M.V. Mateos |
15.10 – 15.30 |
Lenalidomide
M. Boccadoro |
15.30 – 15.50 |
Is there a role for autologous stem-cell transplantation?
H. Einsele |
15.50 – 16.10 |
Panel discussion: Optimal treatment of elderly patients: questions to be adressed in randomised trials.
J. San Miguel, M.V. Mateos, M. Boccadoro, H. Einsele |
16.10 – 16.30 |
Coffee Break |
|
|
SESSION III: Fighting the disease: maximizing benefits while minimizing side-effects
Chair: H. Ludwig |
12 minute presentations are preceded and followed by interactive questions using a keypad and followed by 8 minute discussion |
16.30 – 16.50 |
Renal Failure
H. Ludwig |
16.50 – 17.10 |
The bone and the expert: what is the 2009 consensus?
E. Terpos |
17.10 – 17.30 |
Side effects of new therapies: how to prevent and handle
A. Palumbo |
17.30 |
Closure of the day. |
20.00 |
Depart from the hotel lobby to Course Dinner. |
|
|
SATURDAY MAY 16, 2008 |
SESSION IV: The role of novel agents in the context of transplantation
Chair: JL Harousseau |
12 minute presentations are preceded and followed by interactive questions using a keypad followed by a 5 minute group discussion |
08.30 – 08.50 |
Induction treatment prior to autologous stem cell transplantation
M. Cavo |
08.50 – 09.10 |
Novel agents given before and after autogolous stem cell transplantation
M. Attal |
09.10 – 09.30 |
The role of novel agents in allogeneic stem-cell transplantation
N. Kröger |
09.30 – 09.50 |
Panel Discussion: Optimal treatment of younger patients: questions to be addressed in randomized trials
J.L. Harousseau, M. Cavo, M Attal, P. Sonneveld, N. Kröger |
09.50 – 10.10 |
Coffee Break |
| |
SESSION V: Treatment of relapsed disease
Chair: P. Sonneveld |
Each 12 minute presentation is preceded and followed by one interactive question using a keypad followed by 8 minutes discussion |
10.10 – 10.30 |
How to design and interpret clinical trials in relapsed Multiple Myeloma: definition of the population and of the objectives
M. Delforge |
10.30 – 10.50 |
Novel agents in evaluation
E. Ocio |
10.50 – 11.10 |
Panel discussion: Current strategies in relapsed Multiple Myeloma
All speakers |
| |
SESSION VI: Current algorithms and future perspectives
Chair: J. San Miguel |
Each 12 minute presentation is preceded and followed by one interactive question using a keypad followed by 8 minutes discussion |
11.10 – 11.30 |
The use of new genetic tools for prognostication in Multiple Myeloma -introduction on risk-adapted strategy
H. Avet-Loiseau |
11.30 – 11.50 |
Should complete remission be the primary objective of therapy?
J.L. Harousseau |
11.50 – 12.10 |
The role of continuous therapy: searching for the cure or changing Multiple Myeloma into a chronic disease.
P. Sonneveld |
12.10 – 12.20 |
Learning Assessments: Attendees to fill in their evaluation forms and answer 15 questions based on the course. Certificates will be given ONLY afterwards |
12.20 – 14.00 |
Lunch-buffet and certificate delivery
|